1 report

  • NINLARO IS THE FIRST ORAL PROTEASE INHIBITOR AND COULD HAVE AN ECONOMIC BENEFIT OVER INJECTABLES KYPROLIS AND VELCADE

NHS (2015A) NATIONAL CANCER DRUGS FUND LIST VER##. ##.

  • Cancer
  • Hospital
  • Targeted Therapy
  • Therapy
  • Humana Inc.